DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

Summary

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

Eligibility

Age range

18+ years

Sex

Female

Healthy volunteers

No

Interventions

• Drug
  Trastuzumab deruxtecan

  Experimental therapy by intravenous infusion

• Drug
  Rilvegostomig

  Experimental therapy by intravenous infusion

• Drug
  Pembrolizumab

  Immunotherapy by intravenous infusion

• Drug
  Carboplatin

  Standard of Care (SoC) chemotherapy by intravenous infusion

• Drug
  Paclitaxel

  Standard of Care (SoC) chemotherapy by intravenous infusion

• Drug
  Docetaxel

  Standard of Care (SoC) chemotherapy by intravenous infusion

Locations (250)